The increasing Prevalence of COPD And Advancement In Treatment Option Have Propelled the Growth of the COPD Treatment Market in the North America Region!
- Himanshu Patni
- December 30, 2023
- HEALTHCARE, NEWS
- COPD Treatment Market, COPD Treatment Market Forecast, COPD Treatment Market Growth, COPD Treatment Market Share, COPD Treatment Market Size, COPD Treatment Market Trends
- 0 Comments
The COPD treatment market is expected to register a CAGR of approx. 5.3% over the period of 2023-2030. Chronic obstructive pulmonary disease (COPD) is a group of diseases that cause airway obstruction and breathing problems. These include emphysema and chronic bronchitis. The increasing prevalence of chronic obstructive pulmonary disease (COPD) and advancements in treatment options are playing a significant role in boosting the COPD treatment market in the United States. COPD is a chronic respiratory condition characterized by airflow limitation and is a leading cause of morbidity and mortality worldwide. The rising prevalence of COPD is primarily attributed to factors such as smoking, environmental pollution, and an ageing population. Furthermore, Advancements in the treatment of COPD, lead to improved outcomes for patients. These advancements include the development of novel medications, innovative delivery systems, and a greater emphasis on personalized treatment approaches. For instance, In 2021, GSK announced positive results from clinical trials evaluating its novel dual bronchodilator therapy for COPD, which combines two long-acting bronchodilators. The therapy demonstrated improved lung function and symptom control in COPD patients, providing a potential treatment option for the growing population of individuals with the disease. Furthermore, Canada has a strong and growing healthcare industry, with a focus on developing cutting-edge therapies and technologies. This has led to significant investments in the research and development of drugs, which in turn has accelerated the adoption of the COPD treatment market. Furthermore, the increasing prevalence of COPD and technological innovations in COPD drugs have synergistically contributed to the growth of the COPD treatment market. Also, Companies like GSK, AstraZeneca, and Boehringer Ingelheim have been at the forefront of introducing novel technologies and digital solutions to enhance COPD management. These advancements not only improve treatment outcomes but also empower patients to actively participate in their healthcare, leading to better disease control.
Access sample report (including graphs, charts, and figures) – https://univdatos.com/get-a-free-sample-form-php/?product_id=44875
Further, the North America COPD Treatment Market is expected to grow at a strong CAGR of 5.3% during the forecast period (2023-2030). In conclusion, the growth of the COPD treatment market in North America is a result of a combination of factors, including the increasing prevalence of COPD, advancements in treatment options, increasing healthcare expenditure, and increasing smoking cessation efforts.
North America COPD treatment Market Revenue (2020-2030)- USD bn
For a detailed analysis of the Global COPD treatment Market browse through – https://univdatos.com/report/copd-treatment-market/
Based on the type, the market has been categorized into chronic bronchitis and emphysema. Among them, the chronic bronchitis segment is expected to grow at the highest CAGR in the market. Chronic bronchitis is a group of lung diseases that causes airflow blockages and breathing issues. It is widespread among smokers and rising at a rapid pace. The prevalence of chronic bronchitis is increasing worldwide, especially among the elderly.
Based on the drug class, the market has been categorized into bronchodilators, corticosteroids, combination drugs, roflumilast (phosphodiesterase-4 inhibitor), and others. Among them, the combination drugs segment is expected to grow at a higher CAGR in the market. Combination therapy uses multiple drugs, such as bronchodilators and corticosteroids, to relieve symptoms of COPD and improve lung function. Combination therapy is gaining in popularity as it offers a more effective treatment of COPD symptoms than monotherapy using only one drug.
Global COPD Treatment Market Segmentation
Market Insight, by Type
· Chronic bronchitis
· Emphysema
Market Insights, by Drug Class
· Bronchodilators
· Corticosteroids
· Combination drugs
· Roflumilast (phosphodiesterase-4 inhibitor)
· Others
Market Insights, by Distribution Channel
· Hospital Pharmacies
· Retails Pharmacies
· Online Pharmacies
Market Insight, by Region
· North America COPD treatment Market
o U.S.
o Canada
o Rest of North America
· Europe COPD treatment Market
o Germany
o U.K.
o France
o Italy
o Spain
o Rest of Europe
· Asia-Pacific COPD treatment Market
o China
o India
o Japan
o Rest of Asia-Pacific
· Rest of the World COPD treatment Market
Top Company Profiles
· GSK plc
· Cipla Inc.
· Boehringer Ingelheim
· Verona Pharma plc
· Circassia Group PLC
· Pfizer Inc
· Sanofi
· Almirall, S.A
· Teva Pharmaceutical Industries Ltd.
· Astellas Pharma Inc.
Related Posts
